### Index

activities of daily living. See ADL
AD (Alzheimer’s disease)
  atypical presentation, 62, 69
case study, 13–15, 55–7, 59–61
diagnostic criteria, 11, 23, 51, 62
ey early detection, desirability of, 23
ethics of transplantation in, 268–70
focal cortical presentation, 78
hepatic encephalopathy with, 267–8
case study, 265–7
long-term memory
  FCSRT, 9
  storage impairment, 9, 10
mixed dementia and, 50–3
onset, 2, 23, 61
age of, 76
PCA and, 67, 68, 69
SCI and, 15–16
symptoms, 60, 61
with CAA case study, 71–5
with cerebrovascular disease, 38
ADL (activities of daily living)
  AD with CAA, 71, 74
  basic, 2
corticobasal syndrome case study,
  124, 125–7
decline, diagnosis and, 1, 2
instrumental, 2
MCI and, 23
MELAS case study, 272
post-stroke, 36
PSP, PNFA and, case study, 243
uncategorized dementia case study, 132, 133, 135
vascular dementia, post-stroke, case study,
  157, 158
adult polyglucosan body disease, 211–13
case study, 211, 213
aggressivity, 2
AD case study, 56
aging, normal, SCI in, 8
attention deficit, 10
retrieval deficit, 9
agitation, 2
  DLB case study, 150
vascular dementia case study, 141
agnosia
  associative, 86
  DLB case study, 150
PCA, 67
semantic dementia, 86, 87
AIDS dementia complex, 183
case study, 180–3, 186
alien limb, corticobasal syndrome, 129
case study, 124, 125
ALS (amyotrophic lateral sclerosis), 95
  FTD with, 95–6
case study, 90–4, 109
  genetics, 112
Alzheimer type, dementia of
case study, 18–23
diagnosis, 21
ubcategorizer dementia diagnosed as,
  135, 136
Alzheimer’s disease. See AD
amyloid. See also CAA
deposition in CAA, 76
amyotrophic lateral sclerosis. See ALS
anticholinesterase, response, AD and, 78
anti-retroviral therapy
  AIDS/HIV cognitive disorder, 183
case study, 181
HIV-associated neurocognitive disorder, 185
anxiety
  AD case study, 58
  attention disorder and, 10
  DLB, 151
apathy, 2, 162
  AD case study, 56
  DLB, 151
case study, 148
FTLD behavioral variant, case study, 115, 119
MCI, 57
neurotoxic solvent encephalopathy,
case study, 201
<table>
<thead>
<tr>
<th>Page(s)</th>
<th>Index</th>
</tr>
</thead>
</table>
| 165, 167, 169 | Parkinson disease dementia, 44
| 230 | PSP, 233
| 118 | case study, 230
| 165, 167, 169 | syphilis with dementia, case study, 165, 167, 169
| 31 | treatment, 31
| 84 | aphasia. See also language, speech
| 75 | DLB case study, 149
| 118 | FTLD, behavioral variant, case study, 118
| 78, 85, 101 | logopenic progressive, 78, 85, 101
| 272 | MELAS case study, 272
| 68 | PCA, 68
| 98–101 | primary progressive, 75
| 101 | AD and, 78
| 84 | PNFA, 101
| 101 | semantic dementia, 84
| 110 | progressive non-fluent, 84, 101–4
| 100 | case study, 98–101
| 233, 243 | PSP and, 233, 243
| 238–42 | PSP and, case study, 238–42
| 156 | vascular dementia, post-stroke, case study, 156
| 128–30 | apraxia
corticobasal syndrome, 128–30
| 125–7 | case study, 125–7
| 150 | DLB case study, 150
| 99 | PNFA case study, 99
| 241 | PSP, PNFA and, case study, 241
| 261 | ataxia in Wernicke's encephalopathy with dementia case study, 261
| 7 | attention
disorder, 7, 9, 10
| 59–61 | impairment
DLB, 151
| 208–11 | syphilis with dementia, 170
| 183, 186 | processes
memory and, 8
| 211 | blood tests, 3
| 149 | Boston Naming Test
DLB case study, 149
| 239 | PSP, PNFA and, case study, 239
| 175 | bovine spongiform encephalopathy, 175
| 183, 186 | California Verbal Learning Test
PCA case study, 65
| 139, 142, 143, 144 | case study
Binswanger's disease, 39, 143
| 210, 212 | bipyramidal disorder in adult polyglucosan body disease, 210, 212
| 211 | case study, 211
| 215–17 | Huntington disease, 215–17
| 13–15 | MCI, 13–15
| 201–4 | neurotoxic solvent encephalopathy, 201–4
| 64–7 | PCA, 64–7
| 238–42 | PNFA, PSP and, 238–42
| 253–6 | SCI, 13–15
| 139 | MSA, 139
| 142, 143, 144 | vascular dementia, 143
case study, 139, 141, 142, 143, 144
| 148–50 | AD, 55–7
| 71–5 | AD with CAA, 71–5
| 208–11 | adult polyglucosan body disease, 208–11
| 183, 186 | AIDS/HIV cognitive disorder, 183, 186
| 222–4, 226 | CJD, 222–4
| 124–7 | corticobasal syndrome, 124–7
dementia of Alzheimer type, 18–23
| 148–50 | DLB, 148–50
| 105–10 | FTD with PNFA, 105–10
| 90–4, 109 | FTD, ALS with, 90–4
| 115–19 | FTLD behavioral variant, 115–19
| 105–10 | FTLD with motor neuron disease, 105–10
| 188–90 | Gerstmann–Sträussler–Scheinker syndrome, 188–90
| 277–9 | case study, 277–9
| 265–7 | hepatic encephalopathy with Alzheimer's, 265–7
| 215–17 | Huntington disease, 215–17
| 13–15 | MCI, 13–15
| 222–4 | MELAS, 222–4
| 51–2 | mixed dementia, 47–50
| 245–9 | MSA, NPH with, case study, 245–9
| 33–6 | multi-infarct dementia, 33–6
| 201–4 | neurotoxic solvent encephalopathy, 201–4
| 64–7 | PCA, 64–7
| 239–31 | PNFA, 239–31
| 253–6 | SCI, 13–15

© in this web service Cambridge University Press
www.cambridge.org
Index

case study (cont.)
semantic dementia, 82–4
subjective memory complaints, 13–15
syphilis with dementia, 165–9, 193–6
uncategorized dementia, 132–6
vascular cognitive impairment, 26–9, 30–1
vascular dementia, 141
Wernicke's encephalopathy, 172–5
with dementia, 259–62
cerebral amyloid angiopathy, 76–8
AD with, case study, 71–3
cerebrospinal fluid. See CSF
chorea in Huntington disease, 218, 220
CJD (Creutzfeldt–Jakob disease), 175, 224–8
case study, 222–4, 226
iatrogenic, 225
cognitive
decline
CJD, case study, 222, 224
definition of dementia, 1
DLB case study, 148
intra-individual, 23
MSA, NPH with, case study, 245, 249
syphilis with dementia, 196
Wernicke's encephalopathy with dementia
cause, 259, 260, 261
fluctuation
DLB, 151
DLB case study, 149
Parkinson disease dementia, 3
impairment. See MCI, SCI, vascular cognitive
impairment
AIDS/HIV cognitive disorder case study,
181, 183
HIV-associated, 183–6
PSF, 232
syphilis with dementia, 170
syphilis with dementia case study,
166, 169
Wernicke's encephalopathy, 175
profile in DLB, 150–1
status in syphilis with dementia case
study, 168
symptoms
AD, 3, 62
AD case study, 56, 60
diagnosis, 205–7
DLB, 3
FTD, 3
hepatic encephalopathy, 268
hepatic encephalopathy with Alzheimer's
case study, 265–7
Huntington disease case study, 215
MELAS, 274
MELAS case study, 272
mixed dementia, 50
mixed dementia case study, 48, 51
Parkinson disease dementia, 44
Parkinson disease dementia case study,
42–3
PCA case study, 64
post-stroke, 35, 38, 51
vascular cognitive disease, 30
vascular cognitive disease case
study, 28
vascular dementia case study, 140,
141, 142
tests, 2, 3. See also particular tests
DLB case study, 148
consensus approach to diagnosis, 4
corticobasal degeneration, 127
PCA and, 68
corticobasal syndrome, 128–30
AD and, 78
case study, 124–7
PNFA and, 102
Creutzfeldt–Jakob disease. See CJD
criteria, diagnostic
AD, 9, 11, 23, 51
ALS, 95
Alzheimer's disease, 62
CAA, 77
cognitive complaints, 205–7
corticobasal syndrome, 128
FTD, 95
MCI, 21, 23–4
Parkinson disease dementia, 44
PNFA, 102
semantic dementia, 85, 86
vascular dementia, 36, 159
CSF (cerebrospinal fluid)
abnormality
AD, 62
MCI case study, 15
mild cognitive impairment, 15
SCI, 15
AIDS/HIV cognitive disorder case
study, 181
CJD case study, 223
dynamics
Index

MSA, NPH with, case study, 245, 246
NPH, 250
HIV-associated neurocognitive disorder, 185
PCA case study, 66
syphilis with dementia, 198
case study, 195, 197
CT, 3
Huntington disease case study, 216
MELAS, 275
mixed dementia case study, 48, 51
Parkinson disease dementia case study, 43
uncategorized dementia case study, 134
deafness, affects assessment, 137
definition of dementia, 1, 2
delusions, 2
AD, case study, 56, 58
Parkinson disease dementia, 44
vascular dementia, 144
case study, 141
dementia
AIDS case study, 180–3, 186
Alzheimer type, uncategorized dementia diagnosed as, 135
atypical presentation, 136–8
definition of, 1, 2
frontotemporal, 76, 95, 110
ALS with, 95–6
ALS with, case study, 90–4, 109
ALS with, genetics, 112
geneic forms, 111
onset, 3
uncategorized dementia diagnosed as, 134, 136
gait and, 249
Huntington disease, 217, 218
MELAS and, 272, 274
mixed, 4, 38, 50–3
case study, 47–50, 51–2
multi-infarct, 35–7, 225
case study, 33–6
of Alzheimer type
case study, 18–23
diagnosis, 21
Parkinson disease, 43–5
case study, 42–3
onset, 3
post-stroke, 29–30, 35–40, 51
case study, 155–60
prion diseases and, 224
rapidly progressive, differential diagnosis, 176
SCI and, 15
semantic, 86, 88, 101, 110, 243
case study, 82–4
strategic infarct, 38
uncategorized, case study, 132–6
vascular, 36–40, 225
case study, 139–42
mixed dementia and, 50–3
post-stroke, case study, 155–60
subcortical ischemic, 143
subtypes, 142
symptoms, 143
Wernicke’s encephalopathy case study, 172
with Lewy bodies, 150, 225
case study, 148–50
onset, 3
PCA and, 68
Dementia Rating Scale
DLB, case study, 149
syphilis with dementia case study, 195, 196
depression
attention disorder and, 10
co-existing, 4
treatment, 31
DLB case study, 150
FTD with PNFA case study, 108
Huntington disease case study, 215
MCI, 57
Parkinson disease dementia, 44
post-stroke, 162
syphilis with dementia diagnosed as, 165
vascular, 162
vascular dementia case study, 139, 141
vascular dementia, post-stroke, case study, 135, 158, 160
detection, early
benefits of
AD, 23
CAA, 77
PCA, 69
subcortical vascular dementia, 39, 40
importance of in ALS, 96
diagnosis
AD, 62
desirability of early, 23
CAA, 77
Index

diagnosis (cont.)
CJD, 227
co-existing morbidities, 268

cognitive complaints, 205–7
criteria for
AD, 9, 11, 23, 51, 62
ALS, 95
CAA, 77
cognitive complaints, 205–7
corticobasal syndrome, 128
FTD, 95
MCI, 21, 23–4
Parkinson disease dementia, 44
PNFA, 102
semantic dementia, 85, 86
vascular dementia, 36, 159
definition of dementia, 2
dementia, 1–2
advice on, 3
cause, 2–3
complementary tests, 3
definition, 1
future progress, 4
of Alzheimer type, 21
differential, 2
rapidly progressive dementia, 176
FTLD behavioral variant, 118, 119, 120
Gerstmann–Straussler–Scheinker syndrome, 280
marijuana use and, 190
MELAS, 275
PCA, 69
PPA, 243
PSP, 234, 257
SCI, 11, 16
subcortical vascular dementia,
desirability of early, 40
syphilis with dementia, 198
dizziness, AIDS/HIV cognitive disorder case study, 180
drug therapy
AIDS/HIV cognitive disorder case study, 181
DLB, 152
effects in dementia, 52
HIV-associated neurocognitive disorder, 185
Huntington disease, 220
Parkinson disease dementia, 44
PNFA, 103
semantic dementia, 88
side effects, attention disorder, 10
syphilis with dementia, 170, 197
case study, 168, 195
vascular dementia case study, 141
dysexecutive syndrome, 30, 31
subcortical vascular dementia and, 39
symptoms, 39
dysphagia
PSP, PNFA and, case study, 242
Wernicke’s encephalopathy case study, 172,
175–7
electroencephalography, 3
AD case study, 60
adult polyglucosan body disease case study, 209
CJD, 226, 227
case study, 223
Gerstmann–Straussler–Scheinker syndrome
case study, 278
hepatic encephalopathy with Alzheimer’s case study, 266
mixed dementia case study, 48
PNFA, 102, 103
SCI, 15
vascular dementia, post-stroke case study, 155, 157
Wernicke’s encephalopathy case study, 174
encephalopathy
hepatic, 268
with Alzheimer’s, 267–8
with Alzheimer’s, case study, 265–7
solvent. See neurotoxic solvent
encephalopathy
ethics of transplantation in AD, 268–70
executive abilities
AD and, 51
adult polyglucosan body disease, 212
case study, 208, 209, 211
decline, diagnosis and, 1
DLB, 151
hepatic encephalopathy with Alzheimer’s case study, 265
Huntington disease case study, 215
mixed dementia case study, 48
neurotoxic solvent encephalopathy case study, 201, 202
Parkinson disease dementia, 44
PNFA, 101
PSP, PNFA and, case study, 239
subcortical vascular dementia and, 39
syphilis with dementia case study, 169
vascular cognitive impairment, 30, 31
case study, 28, 29
vascular dementia, post-stroke case study, 156, 159
executive dysfunction
Huntington disease, 218–19
PSP, 232
case study, 229, 254, 256
syphilis with dementia, 170
case study, 166, 168, 196, 197
vascular lesions and, 162
EXIT25 in FTD, behavioral variant, case study, 116

FAB (Frontal Assessment Battery)
adult polyglucosan body disease case study, 209
ALS with FTD case study, 93
executive ability and, 30
FTD with PNFA case study, 107, 109
PSP, 233
case study, 230
uncategorized dementia case study, 134, 136
falls
PSP, 256
case study, 253, 256
PNFA and, case study, 242
Wernicke’s encephalopathy with dementia
case study, 259
Free and Cued Selected Recall Test, 9–10
Frontal Assessment Battery, 233
frontal lobe dysfunction in dementia with
atypical presentation, 137
frontotemporal dementia. See FTD
frontotemporal lobar degeneration. See FTLD
FTD (frontotemporal lobar degeneration), 85
behavioral variant, 119–22
case study, 115–19
subtypes, 120
with motor neuron disease case study, 105–10
gait. See also walking
AIDS/HIV cognitive disorder case study, 181, 183
dementia and, 249
DLB case study, 149
Gerstmann–Straussler–Scheinker syndrome
case study, 278
HIV-associated neurocognitive disorder, 184
Huntington disease case study, 216
MSA, NPH with, 249
case study, 245, 249
NPH, 250
Parkinson disease, 43, 250
PSP
case study, 229, 230, 253, 254
PNFA and, case study, 242
vascular dementia case study, 140
Wernicke’s encephalopathy with dementia
case study, 259, 260, 261
genetics
CJD, 224, 226
Gerstmann–Straussler–Scheinker syndrome,
279, 280
Huntington disease, 217
Gerstmann syndrome PCA, 67
Gerstmann–Straussler–Scheinker syndrome,
190, 225, 279–81
case study, 188–90, 277–9
gnosis, diagnosis and, 1
Hachinski Ischemic Scale in vascular dementia
case study, 140
hallucinations, 2
CJD, 226
case study, 222
DLB, 151
case study, 150
Parkinson disease dementia, 44
HDRS (Hamilton Depression Scale) in vascular
dementia case study, 141
hearing impairment, affects assessment, 137
hepatic encephalopathy, 268
Index

Wernicke's encephalopathy with dementia case study, 261–2
marijuana use, confounds diagnosis, 190
Mayo Fluctuations Questionnaire in Parkinson disease dementia, 44
case study, 43
MCI (mild cognitive impairment) case study, 13–15
diagnostic criteria, 21, 23–4
progression to dementia, 23–4
SCI and, 15–16
symptoms, 58
MDRS (Mattis Dementia Rating Scale) case study, 230
PNFA and, case study, 239
vascular dementia case study, 140, 141
MELAS, 274–5
case study, 272–4
memory AD, 62
adult polyglucosan body disease case study, 208, 209, 211
ALS with FTD case study, 91, 93
diagnosis and, 1
disorders, 9
DLB case study, 148, 149
everal complaints, 13
episodic, 8–9
Free and Cued Selected Recall Test, 9–10
Gerstmann–Straussler–Scheinker syndrome case study, 188
haptic encephalopathy with Alzheimer's, case study, 265–6
Huntington disease, 219
MSA, NPH with, case study, 246
neurotoxic solvent encephalopathy case study, 202, 204
PCA case study, 64, 65
PNFA, 101
case study, 99
PSP, 232
case study, 254, 256
PNFA and, case study, 238
subjective complaints, 14, 15, See SCI
syphilis with dementia, 170
case study, 165, 169, 193
vascular cognitive dementia and, case study, 26, 28
vascular dementia, post-stroke, case study, 155, 156, 158, 159
Wernicke's encephalopathy with dementia case study, 260
migraine in AIDS/HIV cognitive disorder case study, 180, 183
mild cognitive impairment, 15
Minnesota Multiphasic Personality Inventory in vascular dementia, post-stroke, case study, 159
mixed dementia, 4, 38, 50–3
case study, 47–50, 51–2
MMSE (Mini-Mental State Examination), 2 AD, 3
case study, 55, 56, 59, 61
with CAA, case study, 72, 74
adult polyglucosan body disease case study, 208, 209, 211
ALS with FTD case study, 91, 93
corticobasal syndrome case study, 126
DLB, 3, 151
case study, 148, 149, 150
everal dementia, 22
eexecutive ability and, 30
FTD, 3
behavioral variant case study, 116
with PNFA case study, 107, 108
Gerstmann–Straussler–Scheinker syndrome case study, 277
mixed dementia case study, 48
MSA, NPH with, case study, 246
neurotoxic solvent encephalopathy case study, 202
Parkinson disease dementia, 44
case study, 42, 43
PCA case study, 65
PSP
case study, 230, 254
PNFA and, case study, 238, 241
syphilis with dementia case study, 166, 195
uncategorized dementia case study, 133, 134, 136
vascular dementia case study, 140, 141
post-stroke, case study, 158
Wernicke's encephalopathy case study, 173
with dementia, case study, 260, 262, 263
mnesic processes, 8–9
MoCA (Montreal Cognitive Assessment), 2, 234
AD with CAA case study, 72
MoCA (Montreal Cognitive Assessment) (cont.)
ALS with FTD case study, 91
FTD with PNFA case study, 107
Gerstmann–Sträussler–Scheinker syndrome case study, 188, 189
Huntington disease case study, 216
mixed dementia case study, 48, 51
neurotoxic solvent encephalopathy case study, 202
motor neuron disease, 95
motor symptoms, 268
AD, 60
AIDS/HIV cognitive disorder case study, 181
ALS case study, 90
ALS with FTD, 95
case study, 92, 93
corticobasal syndrome, 128–30
case study, 124, 125–7
FTD with PNFA case study, 108
HIV-associated neurocognitive disorder, 184
Huntington disease, 217, 218–19
case study, 216
MSA, NPH with, case study, 245, 249
Parkinson disease dementia, 3
PNFA, 102
case study, 98
PSP, 232, 234
case study, 229, 230
PNFA and, case study, 242
vascular cognitive impairment case study, 28
vascular dementia, post-stroke, case study, 156
Wernicke's encephalopathy, 175 case study, 174
movement disorders in DLB case study, 149
MRA in vascular dementia, post-stroke, case study, 156, 160
MRI, 3
AD, 62
case study, 57, 60
with CAA, case study, 72, 75
with CAA case study, 76
adult polyglucosan body disease, 212
case study, 208, 209
AIDS/HIV cognitive disorder case study, 181, 183
ALS with FTD case study, 92
cerebral amyloid angiopathy, 78
CJD, 226, 227
case study, 223
corticobasal syndrome case study, 126
DLB, 152
FTD behavioral variant case study, 117
with PNFA case study, 107
Gerstmann–Sträussler–Scheinker syndrome case study, 189, 278
HIV-associated neurocognitive disorder, 184, 186
MCI case study, 15
MELAS, 274, 275
case study, 273
memory impairment, 11
mixed dementia case study, 48, 51
MSA, NPH with, case study, 245, 246
PCA case study, 66
PNFA, 102, 103
case study, 100
post-stroke, 33, 35
PSP, 234, 257
case study, 230, 255
PNFA and, case study, 240
SCI, 16
semantic dementia, 87
case study, 82
syphilis with dementia case study, 167, 169, 194, 197
vascular dementia, 143
case study, 140, 142
post-stroke case study, 156, 158
Wernicke's encephalopathy case study, 172, 174, 175, 177
with dementia case study, 259
multi-infarct dementia, 35–7, 225
case study, 33–6
multiple system atrophy (MSA), NPH with case study, 245–9
neuroimaging. See also CT, MRI, PET
CJD, 225
FTLD, 121
PCA, 68
post-stroke dementia, 30
PPA, 242
subcortical vascular dementia, 39
neurological assessment
adult polyglucosan body disease case study, 209
AIDS/HIV cognitive disorder case study, 181, 183
ALS with FTD case study, 91, 93
CJD case study, 222
corticobasal syndrome case study, 125
FTD with PNFA case study, 107, 109
Gerstmann–Sträussler–Scheinker syndrome case study, 188, 189, 278
PNFA, 101
FTD behavioral variant case study, 117
PSP case study, 230, 254
syphilis with dementia, 197
case study, 216
vascular dementia case study, 140
post-stroke case study, 155, 156, 158
visual and hearing impairment and, 137
Wernicke’s encephalopathy case study, 174
with dementia, case study, 260
definition of dementia, 2
DLB, 3, 151
MCI, 58
Parkinson disease dementia, 3, 44
case study, 42–3
syphilis with dementia case study, 166
vascular dementia case study, 141
Wernicke’s encephalopathy case study, 172
neuropsychological assessment
AD case study, 60, 61
with CAA, case study, 72, 74
adult polyglucosan body disease, 212
case study, 209
AIDS/HIV cognitive disorder case study, 181, 183
FTD behavioral variant, 120
case study, 117
Gerstmann–Sträussler–Scheinker syndrome case study, 189, 191, 278
hepatic encephalopathy with Alzheimer’s case study, 266
Huntington disease, 218
mixed dementia case study, 48, 51
neurotoxic solvent encephalopathy, 204, 205
case study, 202, 204
PCA case study, 65, 67
PNFA, 102
PSP PNFA and, case study, 239
SCI, 10
syphilis with dementia case study, 166, 195, 196
vascular cognitive impairment case study, 28
vascular dementia case study, 140
post-stroke case study, 158
neurosyphilis, dementia with, 170, 196–8
case study, 165–9, 193–6
neurotoxic solvent encephalopathy, 204, 205
See neurotoxic solvent encephalopathy
case study, 201–4
night-time behaviors, 2
NPI (Neuropsychiatric Inventory), 2
AD case study, 56
DLB case study, 149
Parkinson disease dementia, 44
case study, 43
syphilis with dementia case study, 167
onset, nature of, aids diagnosis, 205
paralysis in syphilis with dementia case study, 193, 196
Parkinson disease
dementia, 3, 43–5
case study, 42–3
symptoms in case study, 42–3
gait, 250
parkinsonism
DLB, 150
case study, 149
Gerstmann–Straussler–Scheinker syndrome, 280
PSP, 231, 234
case study, 255
PNFA and, case study, 242
pathology
Gerstmann–Straussler–Scheinker syndrome
case study, 279
HIV-associated neurocognitive disorder, 184
PCA (posterior cortical atrophy), 64–7
AD and, 67, 68, 69, 78
personal care
FTLD behavioral variant case study,
115, 118
vascular cognitive dementia and, case study, 26
personality
change
FTLD behavioral variant case study,
115–16, 118
Gerstmann–Straussler–Scheinker syndrome case study, 277
Huntington disease, 218
Huntington disease case study, 215
MELAS, 274
neurotoxic solvent encephalopathy case study, 201, 203
PSP case study, 253
semantic dementia, 87
syphilis with dementia, 196
syphilis with dementia case study, 193
disorder, co-existing, 4
PET, 3
AD, 62
cerebral amyloid angiopathy, 78
Gerstmann–Straussler–Scheinker syndrome
case study, 189, 190
MCI case study, 15
neurotoxic solvent encephalopathy, 204
case study, 201, 202
PCA case study, 67
PNFA, 102, 103
SCI, 16
semantic dementia, 87
storage impairment, 11
uncategorized dementia case study, 134, 136
Pick’s disease. See FTLD
PNFA (progressive non-fluent aphasia), 84,
101–4, 110, 243, See PNFA
case study, 98–101
FTD with case study, 105–10
PSP and, 233, 243
case study, 238–42
polyglucosan bodies, 213, See also adult
polyglucosan body disease
polyneuropathy in adult polyglucosan body
disease, 210
case study, 209, 211
posterior cortical atrophy. See PCA
PPA (primary progressive aphasia), 75,
242–4
AD and, 78
PNFA, 101
semantic dementia, 84
praxis, diagnosis and, 1
primary progressive aphasia. See PPA
prion disease
CJD, 224–8
PCA and, 68
progressive supranuclear palsy. See PSP
pseudobulbar affect
vascular dementia, 144
case study, 139, 141
PSP (progressive supranuclear palsy), 103,
231–6, 256–7
case study, 229–31, 253–6
parkinsonism, 234
PNFA and, 233, 243
case study, 238–42
PSP-parkinsonism, 257
psychiatric symptoms
in dementia, 143
mask dementia, 4
stroke and, 143
psychometric tests
AD study, 19
PSP, 233
psychosis
MELAS, 274
Parkinson disease dementia, 44
vascular dementia, 144
case study, 139
Wernicke’s encephalopathy, 175
pulvinar sign in Wernicke’s encephalopathy case study, 174, 175, 177
Recall. See also memory
deficit
registration impairment and, 8
retrieval impairment and, 9, 10
storage impairment and, 8, 9, 10
registration, mnesic process of, 8, 10
retrieval, mnesic process of, 8, 9
saccades in PSP, 234
case study, 230
safety, balancing patients wishes and, 137
SCI (subjective cognitive impairment), 7, 10,
15–16
case study, 13–15
screening
questions, 1, 2
syphilis, 170, 198
seizures
post-stroke, case study, 26, 29, 31
vascular dementia, post-stroke, case study, 157, 158
self care
FTLD behavioral variant, case study, 115, 118
vascular cognitive dementia and, case study, 26
semantic dementia, 84–9, 101, 110, 243
case study, 82–4
sensory symptoms, post-stroke, 33
sleep
apnea, adverse effects on symptoms, 160
difficulties in syphilis with dementia case study, 167, 168
social abilities FTLD behavioral variant, 119, 120, 121
case study, 115, 117, 118
SPECT
AD
case study, 60, 62
with CAA case study, 72, 74
corticobasal syndrome case study, 126
DLB, 152
FTD, behavioral variant case study, 117
mixed dementia case study, 48
neurotoxic solvent encephalopathy, 204
PNFA, 102, 103
case study, 100
PSP, PNFA and, case study, 240
semantic dementia, 87
case study, 82
syphilis with dementia case study, 194
vascular dementia, 143
vascular disease and, 79
speech
difficulty
FTD with PNFA case study, 105, 108
PNFA case study, 98
PNFA and, 243
post-stroke vascular dementia and case study, 156, 158
PSP and
case study, 230, 253, 256
PNFA and, case study, 239, 241
semantic dementia, 86
syphilis with dementia and case study, 165, 168
therapy
PNFA, 103
semantic dementia, 88
storage, mnesic process of, 8, 9
stroke
CAA and, 77
dementia following, 29–30, 35–40, 51
case study, 155–60
depression following, 162
-like episodes in MELAS, 274
case study, 272–4
neuropsychiatric symptoms following, 143
case study, 142
persistent fetal circulation and, 79
therapy to minimize risk, 30, 34
subcortical
dementia in Huntington disease, 218
ischemic vascular dementia, 143
syndrome, 30
subjective memory complaints, 14, See SCI
case study, 13–15
symptoms
AD, 2, 57, 60, 62
atypical presentation, 62
case study, 55
symptoms (cont.)
ADL, 1
adult polyglucosan body disease case study, 208
AIDS/HIV cognitive disorder case study, 180, 183
ALS with FTD case study, 90
CJD, 175, 225, 226
case study, 222, 224
cognitive, 1
corticobasal syndrome, 128–30
case study, 124, 125–7
DLB, 3, 151
case study, 148
dysexecutive syndrome, 39
FTD, 3
with PNFA, case study, 105–6
FTLD behavioral variant, 119–20
case study, 115–16, 118
Gerstmann–Sträussler–Scheinker syndrome, 280
case study, 277
hepatic encephalopathy, 268
with Alzheimer’s, case study, 265–7
HIV-associated neurocognitive disorder, 183
Huntington disease, 218–19
case study, 215
MCI, 58
MELAS, 274
case study, 272–4
motor, 3
MSA, NPH with, case study, 245, 249
neuropsychiatric, definition of dementia, 2
neurotoxic solvent encephalopathy, 204
case study, 201
Parkinson disease dementia, 3, 44
case study, 42–3
PCA, 67
case study, 64, 67
PSP, 232
case study, 229, 253–6
PNFA and, case study, 238, 241–2
semantic dementia, 85
case study, 82
subcortical vascular dementia, 39
syphilis with dementia, 196
case study, 165, 193
vascular dementia, 143
case study, 139
post-stroke, case study, 156–7
Wernicke’s encephalopathy, 175
case study, 172, 173
with dementia, case study, 259, 260, 261
syphilis
dementia with, 170, 196–8
case study, 163–9, 193–6
screening, 170, 198
tests
cognitive, 3, See also particular tests
cognitive function
Free and Cued Selected Recall Test, 9–10
MMSE, 2
MoCA, 2
Severe Impairment Battery, 2
laboratory, 3
psychometric, in AD study, 19
thiamine in Wernicke’s encephalopathy case study, 174, 175–7, 261
time course
of dementia, 4
of diagnosis, 3
transplantation, ethics of in dementia, 268–70
tremor in DLB case study, 149
ultrasound in mixed dementia case study, 48
Unified Parkinson’s Diseases Rating Scale in DLB case study, 150
vascular
cognitive impairment
case study, 26–9, 30–1
management in case study, 29, 30–1
post-stroke, 29–30
post-stroke, 35–40
sub-types, 37–40
dementia, 36–40, 225
case study, 139–42
mixed dementia and, 50–3
subcortical, 39
subcortical ischemic, 143
subtypes, 142
symptoms, 143
depression, 162
vertigo in CJD, 226
case study, 222
visual disturbances
AIDS/HIV cognitive disorder case study, 181  
CJD, 226  
    case study, 222, 224  
PSP, 234  
    case study, 230, 235, 254, 256  
PNFA and, case study, 241  
Wernicke’s encephalopathy, 175  
    case study, 173  
visual impairment, affects assessment, 137  
visuospatial difficulties  
atypical Alzheimer's presentation, 62  
DLB, 151  
    case study, 148  
PCA, 67, 68  
    case study, 64, 65, 67  
walking. See also gait  
walking difficulties  
    adult polyglucosan body disease, 212  
    case study, 210, 219  
PSP, 232  
watershed infarction, 160–1  
Wernicke’s encephalopathy, 175  
    case study, 172–5  
with dementia, 262  
with dementia case study, 259–62